1. Home
  2. DMC vs ALVO Comparison

DMC vs ALVO Comparison

Compare DMC & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Del Monte Corporation Ordinary Shares

DMC

Del Monte Corporation Ordinary Shares

N/A

Current Price

$25.87

Market Cap

1.2B

Sector

N/A

ML Signal

N/A

Logo Alvotech

ALVO

Alvotech

N/A

Current Price

$4.63

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DMC
ALVO
Founded
1886
2013
Country
Cayman Islands
Luxembourg
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.6B
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
DMC
ALVO
Price
$25.87
$4.63
Analyst Decision
Buy
Buy
Analyst Count
2
7
Target Price
★ $40.60
$7.50
AVG Volume (30 Days)
445.6K
★ 930.1K
Earning Date
10-28-2026
11-11-2026
Dividend Yield
★ 4.55%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 1.04
N/A
Revenue
★ $4,322,300,000.00
N/A
Revenue This Year
$5.40
$10.60
Revenue Next Year
$7.61
$22.47
P/E Ratio
$25.40
★ $18.20
Revenue Growth
★ 0.98
N/A
52 Week Low
$26.09
$2.94
52 Week High
$33.06
$6.53

Technical Indicators

Market Signals
Indicator
DMC
ALVO
Relative Strength Index (RSI) 32.56 46.42
Support Level N/A $3.10
Resistance Level $31.49 $5.43
Average True Range (ATR) 0.95 0.30
MACD -0.11 -0.00
Stochastic Oscillator 3.59 53.41

Price Performance

Historical Comparison
DMC
ALVO

About DMC Del Monte Corporation Ordinary Shares

Del Monte Corp is a producer, marketer, and distributor of fresh, packaged, value-added, and canned food products. Its products are sold in multiple countries and are marketed under the DEL MONTE brand and other brands.

About ALVO Alvotech

Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.

Share on Social Networks: